Effectiveness of the first dose of BNT162b2 vaccine to preventing COVID-19 in healthcare personnel
e202104070
Keywords:
COVID-19, SARS-CoV-2, SARS-CoV-2 vaccine, Vaccine effectiveness, Healthcare personnel, Infection prevention and controlAbstract
Background: A first protective dose of vaccine may allow delaying the second dose in a context of low supply. The objective is to assess the effectiveness of a single dose of vaccine against SARS-CoV-2 (BNT162b2) after twelve days of its administration in healthcare personnel (HCP) of a Health Department.
Methods: A case-control study was made. HCP with suspected COVID-19 and HCP close contacts of COVID-19 cases were included between January 27 and February 7, 2021. They were PCR tested for SARS-CoV-2; those with positive PCR were considered cases and those with negative PCR were considered controls. The crude (VE) and adjusted (VEa) vaccine effectiveness to prevent COVID-19 cases and their 95% confidence interval were calculated using the formula VE = (1-Odds ratio) x 100.
Results: 268 HCP were included, of which 70 (26.1%) were considered cases and 198 (73.9%) controls. The frequency of vaccine exposure in cases was 55.7% vs. 69.7% in controls (p=0.035). The VEa of the first vaccine dose was 52.6% (95%CI: 1.1-77.3). The VEa in the subgroup of HCP studied for suspected disease was 74.6% (CI95%: 38.4-89.5).
Conclusions: One dose of BNT162b2 vaccine against SARS-CoV-2 offers early protection after twelve days of administration. These data could be considered to adapt strategies and consider postponing the second dose in situations of limited vaccine supply in order to achieve the maximum number of people covered with a first dose.
Downloads
References
Johns Hopkins University Coronavirus Resource Center. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. JHU: Baltimore, Maryland; 2020. Disponible en https://coronavirus.jhu.edu/map.html. Consultado el 10/03/2021.
World Health Organization. WHO Director-general’s opening remarks at the media briefing on COVID-19. WHO: Geneva, Switzerland; 2020. Disponible en: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Consultado el 07/03/2021.
European Centre for Disease Prevention and Control. Guidelines for non-pharmaceutical interventions to reduce the impact of COVID-19 in the EU/EEA and the UK. 24 September 2020. ECDC: Stockholm; 2020. Disponible en: https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-guidelines-non-pharmaceutical-interventions-september-2020.pdf. Consultado el 07/03/2021.
European Centre for Disease Prevention and Control. Overview of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA and the UK – 2 December 2020. ECDC: Stockholm; 2020. Disponible en: https://www.ecdc.europa.eu/sites/default/files/documents/Overview-of-EU_EEA-UK-vaccination-deployment-plans.pdf. Consultado el 07/03/2021.
European Centre for Disease Prevention and Control. COVID-19 vaccination and prioritisation strategies in the EU/EEA. 22 December 2020. ECDC: Stockholm; 2020. Disponible en: https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-vaccination-and-prioritisation-strategies.pdf. Consultado el 07/03/2021.
Estrategia de vacunación COVID-19 en España líneas maestras. Actualización 23 de noviembre de 2020. Ministerio de Sanidad. Gobierno de España; 2020. Disponible en: https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-vaccination-and-prioritisation-strategies.pdf. Consultado el 08/02/2021.
Estrategia de vacunación frente a COVID-19 en España. Grupo de Trabajo Técnico de Vacunación COVID-19 de la Ponencia de Programa y Registro de Vacunaciones. Actualización 5. https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID-19_Actualizacion5_EstrategiaVacunacion.pdf. Consultado el 30/03/2021.
European Medicines Agency (EMA). Treatments and vaccines for COVID-19: authorised medicines. EMA: Amsterdan, Netherlands; 2020: Disponible en: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/treatments-vaccines-covid-19-authorised-medicines#covid-19-vaccines-section. Consultado el 21/02/2021.
European Medicines Agency (EMA). Comirnaty -COVID-19 mRNA vaccine (nucleoside-modified). EMA: Amsterdan, Netherlands; 2021. Disponible en: https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty. Consultado el 21/02/2021.
European Medicines Agency (EMA). COVID-19 Vaccine Moderna -COVID-19 mRNA Vaccine (nucleoside modified). EMA: Amsterdan, Netherlands; 2021. Disponible en: https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-moderna. Consultado el 21/02/2021.
European Medicines Agency (EMA). COVID-19 Vaccine AstraZeneca. EMA: Amsterdan, Netherlands; 2021. Disponible en: https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria-previously-covid-19-vaccine-astrazeneca. Consultado el 21/02/2021
European Medicines Agency (EMA). COVID-19 Vaccine Janssen. EMA: Amsterdan, Netherlands; 2021. Disponible en: https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-janssen. Consultado el 17/04/2021.
Polack F, Thomas S, Kitchin N et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020; 383:2603-2615. https://doi.org/10.1056/nejmoa2034577
Baden L, El-Sahly H, Essink B et al. Efficacy and Safety of the mRNA1273 SARS-CoV-2 Vaccine. N Engl J Med 2021; 384:403-416. https://doi.org/10.1056/nejmoa2035389
Dagan N, Barda N, Kepten E et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med 2021; 384:1412-23. https://doi.org/10.1056/NEJMoa2101765
Thompson MG, Burgess JL, Naleway AL et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep 2021;70:495–500. https://doi.org/10.15585/mmwr.mm7013e3
Keehner J, Horton LE, Pfeffer MA et al. SARS-CoV-2 Infection after Vaccination in Health Care Workers in California. N Engl J Med. 2021; https://doi.org/10.1056/NEJMc2101927
Kadire SR, Wachter RM, Lurie N. Delayed Second Dose versus Standard Regimen for Covid-19 Vaccination. N Engl J Med 2021; 384:e28. https://doi.org/10.1056/NEJMclde2101987
Skowronski DM, De Serres G. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2021. https://www.nejm.org/doi/full/10.1056/NEJMc2036242
Voysey M, Clemens SAC, Madji SA et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021; 397:881-91. https://doi.org/10.1016/S0140-6736(21)00432-3
Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada in the context of limited vaccine supply. Government of Canada, Canada; 2021. Disponible en: https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html. Consultado el 16/04/2021.
Agencia Española del Medicamento y Productos Sanitarios. Ficha técnica COMIRNATY concentrado para dispersión inyectable. Pfizer-Biontech. Disponible en https://cima.aemps.es/cima/pdfs/es/ft/1201528001/FT_1201528001.pdf. Consultado el: 28/02/2021.
Estrategia de detección precoz, vigilancia y control de COVID-19. Actualizado a 26 de febrero de 2021. Ministerio de Sanidad. Gobierno de España; 2020. Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/COVID19_Estrategia_vigilancia_y_control_e_indicadores.pdf. Consultado el 27/02/2021.
Hodgson S, Mansatta K, Mallett G et al. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis 2021;21: e26–35. https://doi.org/10.1016/S1473-3099(20)30773-8.
World Health Organization. WHO Target Product Profiles for COVID-19 Vaccines. WHO: Geneva, Switzerland; 2020. Disponible en: https://www.who.int/docs/default-source/blue-print/who-target-product-profiles-for-covid-19-vaccines.pdf. Consultado el 28/02/2021.
DECRETO 2/2021, de 24 de enero, del president de la Generalitat. Diario Oficial de la Generalitat Valenciana; 2021. Disponible en: http://www.dogv.gva.es/datos/2021/01/25/pdf/2021_670.pdf. Consultado el 08/02/2021.
Generalitat Valenciana. Incidencia Acumulada de casos de COVID-19 en Departamento de Salud 19 – Alicante Hospital General. Consellería de Sanitat Universal i Salut Pública. 2021. Disponible en: https://dadesobertes.gva.es/va/dataset/covid-19-casos-confirmats-pcr-casos-pcr-ultims-14-dies-i-persones-mortes-per-departament-2021/resource/2161dd5a-61e2-414e-8534-8ae0c2011b77. Consultado el 08/02/2021.
Amit S, Beni SA, Biber A et al. Post-vaccination COVID-19 among healthcare workers, Israel. Emerg Infect Dis. 2021. https://doi.org/10.3201/eid2704.210016
Kamal A, Hila B, Karine B et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro Surveill. 2021;26(6):pii=2100096. https://doi.org/10.2807/1560-7917.ES.2021.26.6.2100096
Organización Mundial de la Salud. Recomendaciones provisionales para utilizar la vacuna contra la COVID-19 elaborada por Pfizer y BioNTech, BNT162B2, en el marco de la lista de uso en emergencias. OMS: Ginebra, Suiza; 2021. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/338849/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1-spa.pdf?sequence=1&isAllowed=y. Consultado el 28/02/2021.
Editorial: Science advisers: publish evidence behind COVID vaccine dosing strategy. Nature 2021;589:169-170. https://doi.org/10.1038/d41586-021-00045-8
Centers for Disease Control and Prevention. Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States CDC: Atlanta; 2021. Disponible en: https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html. Consultado el 10/03/2021.
Plotkin SA, Halsey N. Accelerate COVID-19 Vaccine Rollout by Delaying the Second Dose of mRNA Vaccines. Clin Infect Dis 2021. https://doi.org/10.1093/cid/ciab068
Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Disponible en: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf. Consultado el 15/04/2021.
Plotkin SA, Orenstein WA, Offit PA. Plotkin’s vaccines. 7th ed. ed. Philadelphia, PA: Elsevier; 2018.
Kadire S, Wachter R, Lurie N. Delayed Second Dose versus Standard Regimen for Covid-19 Vaccination. N Engl J Med 2021;384:e28. https://doi.org/10.1056/NEJMclde2101987
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Paula Gras-Valentí, Pablo Chico-Sánchez, Natividad Algado-Sellés, Natali Juliet Jiménez-Sepúlveda, Isel Lilibeth Gómez-Sotero, Marina Fuster-Pérez, Lidia Cartagena-Llopis, María Sánchez-Valero, Patricia Cerezo-Milán, Iluminada Martínez-Tornero, Laura Tremiño-Sánchez, Verónica Nadal-Morante, Miranda Monerris-Palmer, Ana Esclapez-Martínez, Elena Moreno de Arcos-Fuentes, Irene Escalada-Martín, Isabel Escribano-Cañadas, Esperanza Merino-Lucas, Juan Carlos Rodríguez-Díaz, José Sánchez-Payá
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
